<html xmlns="http://www.w3.org/1999/xhtml" xmlns="http://www.w3.org/1999/xhtml">
 <head xmlns="http://www.w3.org/1999/xhtml">
 <title xmlns="http://www.w3.org/1999/xhtml"></title>
 </head>
 <body xmlns="http://www.w3.org/1999/xhtml">
 
 GlycoMimetics, Inc. GLYC today announced the closing of its 
 underwritten public offering of 8,050,000 shares of its common stock at 
 a public offering price of $11.50 per share, which includes the exercise 
 in full by the underwriters of their option to purchase up to 1,050,000 
 additional shares of common stock. All of the shares in the offering 
 were offered by GlycoMimetics. The aggregate gross proceeds to 
 GlycoMimetics from the offering, before deducting the underwriting 
 discounts and commissions and offering expenses, were approximately 
 $92.6 million.
 
 
 Jefferies LLC and Cowen acted as joint book-running managers for the 
 offering. SunTrust Robinson Humphrey, Inc. acted as lead manager for the 
 offering.
 
 
 A shelf registration statement relating to this offering was filed with 
 the Securities and Exchange Commission (SEC) on March 17, 2015 and 
 declared effective by the SEC on March 24, 2015. The offering was made 
 only by means of a written prospectus and prospectus supplement that 
 form a part of the registration statement. The final prospectus 
 supplement and accompanying prospectus were filed with the SEC on May 
 24, 2017. Copies of the final prospectus supplement and the accompanying 
 prospectus may also be obtained by contacting Jefferies LLC, 
 Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 
 2nd Floor, New York, NY 10022, or by email at <a xmlns="http://www.w3.org/1999/xhtml" href="mailto:Prospectus_Department@Jefferies.com" rel="nofollow" rel="nofollow">Prospectus_Department@Jefferies.com</a>, 
 or by phone at (877) 821-7388; or Cowen and Company, LLC, c/o Broadridge 
 Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, 
 Attention: Prospectus Department, or by phone at (631) 274-2806.
 
 
 This press release shall not constitute an offer to sell or a 
 solicitation of an offer to buy, nor shall there be any sale of these 
 securities in any state or jurisdiction in which such offer, 
 solicitation or sale would be unlawful prior to registration or 
 qualification under the securities laws of any such state or 
 jurisdiction.
 
 
 About GlycoMimetics, Inc.
 
 
 GlycoMimetics is a clinical-stage biotechnology company focused on 
 cancer and sickle cell disease. GlycoMimetics&#39; most advanced drug 
 candidate, rivipansel, a pan-selectin antagonist, is being developed for 
 the treatment of vaso-occlusive crisis in sickle cell disease and is 
 being evaluated in a Phase 3 clinical trial being conducted by its 
 strategic collaborator, Pfizer. GlycoMimetics&#39; wholly-owned drug 
 candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an 
 ongoing Phase 1/2 clinical trial as a potential treatment for AML and in 
 a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also 
 recently initiated a clinical trial with a third drug candidate, 
 GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is 
 located in Rockville, Maryland in the BioHealth Capital Region.
 
 <img xmlns="http://www.w3.org/1999/xhtml" alt="" src="http://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20170530006192r1&amp;sid=benz2&amp;distro=nx&amp;lang=en"></img>View source version on businesswire.com: <a xmlns="http://www.w3.org/1999/xhtml" href="http://www.businesswire.com/news/home/20170530006192/en/" rel="nofollow" rel="nofollow">http://www.businesswire.com/news/home/20170530006192/en/</a></body></html>

Press Releases

GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlycoMimetics (NASDAQ:GLYC)

GlycoMimetics

GLYC

GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

NSYS


Nortech Systems Incorporated (NASDAQ:NSYS), a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products serving the medical, aerospace &amp; defense and

Nortech Systems Incorporated to Report First Quarter 2024 Financial Results and Hold a Conference Call on May 16, 2024

INSW


International Seaways, Inc. (NYSE:INSW) (the &#34;Company&#34; or &#34;INSW&#34;) announced today that it plans to release first quarter 2024 results before market open on Wednesday, May 8, 2024. The Company will host a conference call

International Seaways to Announce First Quarter 2024 Results on May 8, 2024


Higround, the graphic gaming peripheral brand renowned for its groundbreaking collaborations with iconic brands like Pokémon, Dragon Ball Z and Brain Dead, announces a bold new initiative: GRAFX. GRAFX launches

Higround Unveils GRAFX Program: Elevating Self-Expression by Pushing the Boundaries of Peripheral Design

CRSB


Cornerstone Community Bancorp (OTC:CRSB) announced today its financial results for the first quarter ended March 31, 2024.


The Company reported net income of $1,394,000 for the three months ended March 31, 2024

Cornerstone Community Bancorp Reports Financial Results For the First Quarter Ended March 31, 2024


A message from PBIRx Founder &amp; President


A message from PBIRx Founder &amp; President, Patricia Sirowich: PBIRx is a consulting and auditing firm totally focused on the pharmacy benefit for over thirty years.

PBIRx Growth Fueled by Johnson &amp; Johnson ERISA Lawsuit

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Lincoln National Corporation (LNC) Investors